» Articles » PMID: 7943006

Obstetrical and Gynecological Complications in Fragile X Carriers: a Multicenter Study

Overview
Journal Am J Med Genet
Specialty Genetics
Date 1994 Jul 15
PMID 7943006
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

We have conducted a multicenter obstetrical and gynecological survey of women in fragile X families. Included in the study were 131 gene carriers (39 with a full mutation and 92 with a premutation) and 109 noncarriers. Analysis indicated that higher numbers of fragile X gene carriers reported having irregular menses and other gynecological complications. As a group they also experienced cessation of menses prior to age 40 years at a significantly higher rate. The data appear to indicate that the FMR1 gene may play a role in the development and proliferation of oogonia.

Citing Articles

Current Status and Future Prospects of Stem Cell Therapy for Infertile Patients with Premature Ovarian Insufficiency.

Kim H, Kim T Biomolecules. 2024; 14(2).

PMID: 38397479 PMC: 10887045. DOI: 10.3390/biom14020242.


PGT-M for Premature Ovarian Failure Related to CGG Repeat Expansion of the Gene.

Persico T, Tranquillo M, Seracchioli R, Zuccarello D, Sorrentino U Genes (Basel). 2024; 15(1).

PMID: 38275588 PMC: 10815814. DOI: 10.3390/genes15010006.


Astrocytes in fragile X syndrome.

Talvio K, Castren M Front Cell Neurosci. 2024; 17:1322541.

PMID: 38259499 PMC: 10800791. DOI: 10.3389/fncel.2023.1322541.


Fertility preservation in women with benign gynaecological conditions.

Santulli P, Blockeel C, Bourdon M, Coticchio G, Campbell A, De Vos M Hum Reprod Open. 2023; 2023(2):hoad012.

PMID: 37124950 PMC: 10130191. DOI: 10.1093/hropen/hoad012.


Onco-fertility and personalized testing for potential for loss of ovarian reserve in patients undergoing chemotherapy: proposed next steps for development of genetic testing to predict changes in ovarian reserve.

Sun B, Yeh J Fertil Res Pract. 2021; 7(1):13.

PMID: 34193292 PMC: 8244159. DOI: 10.1186/s40738-021-00105-7.